Recursion Pharmaceuticals - Class A (RXRX) closed at $3.88 on November 4, 2026, up 5.4% from the previous close, on volume of 19,141,204 shares (30-day average 26,239,046).
Data as of November 4, 2026.
4-Nov-2026
Bank of America Securities Remains a Hold on Recursion Pharmaceuticals (RXRX)
TipRanks (Wed, 4-Nov 8:52 AM ET)
Most and least shorted mid- to mega-cap healthcare stocks at the end of October
Seeking Alpha News (Tue, 3-Nov 10:00 AM ET)
Most shorted stocks on Wall Street
Seeking Alpha News (Tue, 3-Nov 9:55 AM ET)
Recursion Reports Clinical Progress as Sanofi Options First Candidate
TipRanks (Mon, 2-Nov 5:24 PM ET)
Recursion Pharmaceuticals GAAP EPS of -$0.22 misses by $0.01, revenue of $18.55M beats by $3.74M
Seeking Alpha News (Mon, 2-Nov 4:35 PM ET)
Globe Newswire (Mon, 2-Nov 4:30 PM ET)
Globe Newswire (Mon, 2-Nov 4:25 PM ET)
Recursion Appoints Fred Hassan as Chair of the Board
Globe Newswire (Mon, 2-Nov 4:05 PM ET)
Here are the major earnings after the close Monday
Seeking Alpha News (Mon, 2-Nov 9:00 AM ET)
Options Volatility and Implied Earnings Moves Today, November 02, 2026
TipRanks (Mon, 2-Nov 7:05 AM ET)
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
Recursion Pharmaceuticals - Class A trades on the NASDAQ stock market under the symbol RXRX.
As of November 4, 2026, RXRX stock price climbed to $3.88 with 19,141,204 million shares trading.
RXRX has a beta of 2.48, meaning it tends to be more sensitive to market movements. RXRX has a correlation of 0.20 to the broad based SPY ETF.
RXRX has a market cap of $2.32 billion. This is considered a Mid Cap stock.
Last quarter Recursion Pharmaceuticals - Class A reported $19 million in Revenue and -$.22 earnings per share. This beat revenue expectation by $5 million and exceeded earnings estimates by $.01.
In the last 3 years, RXRX traded as high as $15.74 and as low as $2.77.
The top ETF exchange traded funds that RXRX belongs to (by Net Assets): ARKK, ARKE, VTI, XBI, ARKG.
RXRX has underperformed the market in the last year with a return of -22.4%, while SPY returned +14.7%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in RXRX shares. However, RXRX has outperformed the market in the last 3 month and 2 week periods, returning +17.2% and +6.6%, while SPY returned -0.3% and -0.8%, respectively. This indicates RXRX has been having a stronger performance recently.
RXRX support price is $3.44 and resistance is $3.92 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RXRX shares will trade within this expected range on the day.
